Products for Research Use Only
RegisterLogin

SPHINX31

CAT: 0804-HY-117661-02Size: 10 mM - 1 mLDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-117661-02Size:10 mM - 1 mL
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SPHINX31 is a potent and selective SRPK1 inhibitor, with an IC50 of 5.9 nM. SPHINX31 inhibits phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1) . SPHINX31 also decreases the mRNA expression of pro-angiogenic VEGF-A165a isoform. SPHINX31 can be used to research neovascular eye disease[1][2][3].
CAS Number
1818389-84-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
SRPK; VEGFR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/sphinx31.html
Purity
99.25
Solubility
DMSO : 15 mg/mL (ultrasonic)
Smiles
O=C(NC1=C(N2CCN(CC3=CC=CC=N3)CC2)C=CC(C(F)(F)F)=C1)C4=CC=C(O4)C5=CC=NC=C5
Molecular Formula
C27H24F3N5O2
Molecular Weight
507.51
Precautions
H302, H315, H319, H335
References & Citations
[1]Batson J, et al. Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease. ACS Chem Biol. 2017 Mar 17;12 (3) :825-832.|[2]C. Allen, et al. The SRPK1 inhibitor SPHINX31 prevents increased retinal permeability in a rodent model of diabetes. Acta Ophthalmologica. Volume 95, Issue S259.|[3]Supradit K, et al. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis. Toxicol In Vitro. 2022 Aug;82:105385.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Chemical Information

Sphinx31
CAS Number1818389-84-2
PubChem CID91972002
IUPAC Name5-pyridin-4-yl-N-[2-[4-(pyridin-2-ylmethyl)piperazin-1-yl]-5-(trifluoromethyl)phenyl]furan-2-carboxamide
Molecular FormulaC27H24F3N5O2
Molecular Weight507.5
XLogP4
Topological Polar Surface Area74.5
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count9
Rotatable Bond Count6
Heavy Atom Count37
Formal Charge0
Complexity742
SMILES
C1CN(CCN1CC2=CC=CC=N2)C3=C(C=C(C=C3)C(F)(F)F)NC(=O)C4=CC=C(O4)C5=CC=NC=C5
InChI
InChI=1S/C27H24F3N5O2/c28-27(29,30)20-4-5-23(35-15-13-34(14-16-35)18-21-3-1-2-10-32-21)22(17-20)33-26(36)25-7-6-24(37-25)19-8-11-31-12-9-19/h1-12,17H,13-16,18H2,(H,33,36)
InChIKey
VURLRACCOCGFDB-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Sphinx31
CAS: 1818389-84-2
CID: 91972002
Formula: C27H24F3N5O2
MW: 507.5
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight507.5
XLogP34
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count9
Rotatable Bond Count6
Exact Mass507.18820951
Monoisotopic Mass507.18820951
Topological Polar Surface Area74.5 Ų
Heavy Atom Count37
Formal Charge0
Complexity742
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Related Products

CatalogName
HY-132126-01SPHINX

Alternative Products

CatalogName
MBS3609956-01SPHINX31
A18640-50SPHINX31 50mg
A18640-25SPHINX31 25mg
A18640-5SPHINX31 5mg
A18640-1SPHINX31 1mg
A18640-500SPHINX31 500mg
A18640-100SPHINX31 100mg
A18640-10SPHINX31 10mg
TBI4376-25MGSPHINX31, SRPK1 inhibitor

Popular Products